Table 1 Association between the miR-539 expression levels and clinicopathological characteristics of patients with breast cancer.
From: miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer
Variables | Cases | miR-539 expression | P value | |
|---|---|---|---|---|
Low (n, %) | High (n, %) | |||
All patients | 38 | 25 (65.8) | 13 (34.2) | Â |
Age (years) | Â | Â | Â | 0.307 |
  \( < \)45 | 16 | 12 (31.6) | 4 (10.5) |  |
  \(\ge 45\) | 22 | 13 (34.2) | 9 (23.7) |  |
Primary tumor size (cm) | Â | Â | Â | 0.732 |
  \(\mathrm{ < 2}\) | 19 | 13 (34.2) | 6 (15.8) |  |
  \(\ge 2\) | 19 | 12 (31.6) | 7 (18.4) |  |
Histological subtype | Â | Â | Â | 0.324 |
  Invasive ductal carcinoma | 32 | 20 (52.6) | 12 (31.6) |  |
  others | 6 | 5 (13.2) | 1 (2.6) |  |
AJCC stage | Â | Â | Â | 0.653 |
  I-II | 28 | 19 (50.0) | 9 (23.7) |  |
  III-IV | 10 | 6 (15.8) | 4 (10.5) |  |
Histological grade | Â | Â | Â | 0.207 |
  G1-G2 | 20 | 15 (39.5) | 5 (13.2) |  |
  G3 | 18 | 10 (26.3) | 8 (21.1) |  |
Lymph node metastasis | Â | Â | Â | 0.009 |
  Negative | 21 | 10 (23.6) | 11 (28.9) |  |
  Positive | 17 | 15 (39.5) | 2 (5.3) |  |
Distant metastasis | Â | Â | Â | 0.192 |
  No | 33 | 23 (60.5) | 10 (26.3) |  |
  Yes | 5 | 2 (5.3) | 3 (7.9) |  |
Estrogen receptor | Â | Â | Â | 0.510 |
  Negative | 12 | 7 (18.4) | 5 (13.2) |  |
  Positive | 26 | 18 (47.4) | 8 (21.1) |  |
